Drugs

, Volume 57, Issue 4, pp 535–544

Treatment of Epilepsy in Pregnancy

Disease Management

Abstract

Pregnant women with epilepsy constitute 0.5% of all pregnancies. Proper seizure control is the primary goal in treating women with epilepsy. The commonly used anticonvulsants are established human teratogens. Factors such as epilepsy, anticonvulsant-induced teratogenicity, patient’s genetic predisposition and the severity of convulsive disorder may attribute to adverse pregnancy outcome for the children of women with epilepsy. Anticonvulsant interaction with folic acid and phytomenadione (vitamin K) metabolism may lead to an increased risk for neural tube defect and early neonatal bleeding. Psychological, hormonal and pharmacokinetic changes in pregnancy may escalate seizure activity.

Preconceptional counselling should include patient education to ensure a clear understanding of risks of uncontrolled seizures and possible teratogenicity of anticonvulsants. Genetic counselling should be performed if both parents have epilepsy or the disease is inherited. Seizure control should be achieved at least 6 months prior to conception and, if clinically possible, by the lowest effective dose of a single anticonvulsant according to the type of epilepsy. The new anticonvulsants are not recommended in pregnancy and require further research to prove their safety in humans.

Folic acid 5 mg/day should be administered 3 months before conception and during the first trimester to prevent folic acid deficiency-induced malformations. Antenatal management should include assessment of patients for anticonvulsant-associated birth defects through detailed ultrasound examination and levels of maternal serum α-fetoproteins. Therapeutic drug monitoring should be performed monthly, or as clinically indicated. If phénobarbital, carbamazepine or phenytoin is administered, maternal phytomenadione supplementation should begin 4 weeks before the expected date of delivery.

In order to prevent convulsions during labour, proper seizure control should be achieved during the third trimester. Benzodiazepines or phenytoin are found to be effective for seizure cessation during labour and delivery. Phytomenadione should be administered immediately after birth to the newborn. The neonate should be assessed carefully for epilepsy and anticonvulsant-associated dysmorphology. Advising the patient on postpartum management regarding contraception and breast-feeding will help maximise the best possible outcome for the newborn and mother. With proper preconceptional, antenatal and postpartum management up to 95% of these pregnancies have been reported to have favourable outcomes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980; 21(3): 261–71PubMedCrossRefGoogle Scholar
  2. 2.
    Byrne B. Epilepsy and pregnancy. Ir Med J 1997; 90: 173–4Google Scholar
  3. 3.
    Yerby MS. Pregnancy and epilepsy. Epilepsia 1991; 32 Suppl. 6: S51–9PubMedCrossRefGoogle Scholar
  4. 4.
    Medeiros YS, Calixto JB. Inhibitory effect of diphenylhydantoin on myometrium from pregnant women in vitro. A comparative study with nicardipine and trifluoperazine. Pharmacol Res 1990; 22(5): 597–603Google Scholar
  5. 5.
    Nappi C, Meo R, Di Carlo C, et al. Reduced fertility and neuroendocrine dysfunction in women with epilepsy. Gynecol Endocrinol 1994; 8: 133–45PubMedCrossRefGoogle Scholar
  6. 6.
    Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995; 36: 676–81PubMedCrossRefGoogle Scholar
  7. 7.
    Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383–8PubMedCrossRefGoogle Scholar
  8. 8.
    Kaneko S. Antiepileptic drug therapy and reproductive consequences: functional and morphological effects. Reprod Toxicol 1991; 5(3): 179–98PubMedCrossRefGoogle Scholar
  9. 9.
    Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997; 68(1): 18–24PubMedCrossRefGoogle Scholar
  10. 10.
    Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of anti-epileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29: 459–67PubMedCrossRefGoogle Scholar
  11. 11.
    Janz D. On major malformations and minor anomalies in the offspring of parents with epilepsy: review of the literature. In: Janz D, Dam M, Richens A, et al. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 211–22Google Scholar
  12. 12.
    Majewski F, Steger M, Richter B, et al. The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Int J Biol Res Pregnancy 1981; 2(1): 37–45PubMedGoogle Scholar
  13. 13.
    Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod Toxicol 1991; 5(4): 301–35PubMedCrossRefGoogle Scholar
  14. 14.
    Finnel RM, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992; 42 (4 Suppl. 5): 25–31Google Scholar
  15. 15.
    Buehler BA, Delimout D, Van Waes M, et al. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990; 322(22): 1567–72PubMedCrossRefGoogle Scholar
  16. 16.
    Lindhout D, Hoppener RJ, Meinardi H. Teratogenicity of anti-epileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984; 25(1): 77–83PubMedCrossRefGoogle Scholar
  17. 17.
    Sulik KK, Johnston MC, Daft PA, et al. Fetal Alcohol Syndrome and DiGeorge anomaly: critical ethanol exposure periods for craniofacial malformations as illustrated in an animal model. Am J Med Genet 1986; Suppl. 2: 97–112CrossRefGoogle Scholar
  18. 18.
    Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counselling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42 (4 Suppl. 5): 149–60PubMedGoogle Scholar
  19. 19.
    Chronology of neural development. In: Spreen O, Tupper D, Risser A, et al. Human developmental neuropsychology. Oxford: Oxford University Press, 1984: 26–8Google Scholar
  20. 20.
    Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976; 89(4): 662–8PubMedCrossRefGoogle Scholar
  21. 21.
    Gaily E, Granstrom ML. Minor anomalies in children of mothers with epilepsy. Neurology 1992; 42 (4 Suppl. 5): 128–31PubMedGoogle Scholar
  22. 22.
    Gaily E, Granstrom ML, Hiilesmaa V, et al. Minor anomalies in the offspring of epileptic mothers. J Pediatr 1988; 112: 520–9PubMedCrossRefGoogle Scholar
  23. 23.
    Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324(10): 674–7PubMedCrossRefGoogle Scholar
  24. 24.
    Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of Spina Bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42 (4 Suppl. 5): 119–25PubMedGoogle Scholar
  25. 25.
    Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1993; 271(10); 767–70CrossRefGoogle Scholar
  26. 26.
    Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996; 75(6): 517–20PubMedCrossRefGoogle Scholar
  27. 27.
    Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320(25): 1661–6PubMedCrossRefGoogle Scholar
  28. 28.
    Koch S, Jager-Roman E, Losche G, et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological oncome. Acta Paediatr 1996; 85(6): 739–46PubMedCrossRefGoogle Scholar
  29. 29.
    Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8(1): 75–8PubMedCrossRefGoogle Scholar
  30. 30.
    Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992; 42 (4 Suppl. 5): 32–42PubMedGoogle Scholar
  31. 31.
    MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338(8760): 131–7CrossRefGoogle Scholar
  32. 32.
    Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334(3): 168–75PubMedCrossRefGoogle Scholar
  33. 33.
    Malone FD, D’Alton ME. Drugs in pregnancy: anticonvulsants. Semin Perinatol 1997; 21(2): 114–23PubMedCrossRefGoogle Scholar
  34. 34.
    Shuster EA. Epilepsy in women (Symposium on Epilepsy — Pt. VII). Mayo Clin Proc 1996; 71(10): 991–9Google Scholar
  35. 35.
    Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985: 26: 631–5PubMedCrossRefGoogle Scholar
  36. 36.
    Lopes-Cendes I, Andermann E, Candes F, et al. Risk factors for changes in seizure frequency during pregnancy of epileptic women: Acohort study [abstract]. Epilepsia 1992; 33 Suppl. 3: 57Google Scholar
  37. 37.
    Hiilesmaa VK. Pregnancy and birth in women with epilepsy. Neurology 1992; 42 (4 Suppl. 5): 8–11PubMedGoogle Scholar
  38. 38.
    Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997; 33(5): 328–43PubMedCrossRefGoogle Scholar
  39. 39.
    Morrell MJ. Hormones, reproductive health and epilepsy. In: Wyllie E, editor. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore (MD): Williams & Wilkins, 1997: 179–87Google Scholar
  40. 40.
    Koren G. Changes in drug disposition in pregnancy and their clinical implications. In: Koren G, editor. Maternal-fetal toxicology: a clinician’s guide. 2nd rev. ed. New York: Marcel Dekker, Inc., 1994: 3–13Google Scholar
  41. 41.
    Pirani BB, Campbell DM, MacGillivray I. Plasma volume in normal first pregnancy. J Obstet Gynaecol Br Commonw 1973; 80(10): 884–7PubMedCrossRefGoogle Scholar
  42. 42.
    Riva R, Albani F, Contin M, et al. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 1996; 6: 470–93CrossRefGoogle Scholar
  43. 43.
    Yerby MS, Freil PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992; 42 Suppl. 5: 12–6PubMedGoogle Scholar
  44. 44.
    Davison JM, Hytten FE. Glomerular filtration during and after pregnancy. J Obstet Gynaecol Br Commonw 1974; 81(8): 588–95PubMedCrossRefGoogle Scholar
  45. 45.
    Dunihoo DR. Maternal physiology. In: Dunihoo DR, editor. Fundamentals of gynecology and obstetrics. Philadelphia (PA): J.B. Lippincott Co., 1992: 280–4Google Scholar
  46. 46.
    Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit 1985; 7(3): 269–73PubMedCrossRefGoogle Scholar
  47. 47.
    Tomson T, Almkvist O, Nilsson BY, et al. Carbamazepine-10, 11-epoxide in epilepsy. A pilot study. Arch Neurol 1990; 47(8): 888–992CrossRefGoogle Scholar
  48. 48.
    Bourgeois BFD, Wad N. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10, 11-epoxide in mice. J Pharmacol Exp Ther 1984; 231: 411–5PubMedGoogle Scholar
  49. 49.
    Armijo JA, Cavada E. Graphic estimation of phenytoin dose in adults and children. Ther Drug Monit 1991; 13(6): 507–10PubMedCrossRefGoogle Scholar
  50. 50.
    Brodie MJ. Management of epilepsy during pregnancy and lactation. Lancet 1990; 336(8712): 426–7PubMedCrossRefGoogle Scholar
  51. 51.
    Perucca E, Richens A, Ruprah M. Serum protein binding of phenytoin in pregnant women. Proc Br Pharmacol Soc 1981; 11: 409P-10PGoogle Scholar
  52. 52.
    Bologa M, Tang B, Klein J, et al. Pregnancy-induced changes in drug metabolism in epileptic women. J Pharmacol Exp Ther 1991; 257(2): 735–40PubMedGoogle Scholar
  53. 53.
    Thomson AH, Brodie MJ. Pharmacokinetics optimisation of anticonvulsant therapy. Clin Pharmacokinet 1992; 23(3): 216–30PubMedCrossRefGoogle Scholar
  54. 54.
    Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study of 100 children with epilepsy. Acta Neurol Scand 1982; 65(5): 504–23PubMedCrossRefGoogle Scholar
  55. 55.
    Pugh CB, Garnett WR. Current issues in the treatment of epilepsy. Clin Pharm 1991; 10(5): 335–58PubMedGoogle Scholar
  56. 56.
    Wilson JG. Current status of teratology — general principles and mechanisms derived from animal studies. In: Wilson JG, Fraser FC, editors. Handbook of teratology. Vol. 1. New York: Plenum Press, 1977: 47–74Google Scholar
  57. 57.
    Reife RA. Topiramate: a novel antiepileptic agent. In: Shorvan SD, et al., editors. The treatment of epilepsy. Oxford: Black-wen Science, 1996: 471–81Google Scholar
  58. 58.
    Lamotrigine Pregnancy Registry. International interim update. 1st Septmeber 1992 through 31 March 1998. Issued June 1998. Glaxo WellcomeGoogle Scholar
  59. 59.
    Van Creveld S. Nouveau aspects de la maladie héimorragique du nouveau-vie [in French]. Arch Fr Pediatr 1958; 6: 721–35Google Scholar
  60. 60.
    Moslet U, Hansen ES. A review of vitamin K, epilepsy and pregnancy. Acta Neurol Scand 1992; 85(1): 39–43PubMedCrossRefGoogle Scholar
  61. 61.
    Sutor AH. Vitamin K deficiency bleeding in infants and children. Semin Thromb Hemost 1995; 21(3) 317–29PubMedCrossRefGoogle Scholar
  62. 62.
    Anai T, Hirota Y, Oga M, et al. PIVKA-II (protein induced by vitamin K absence-II) status in newborns exposed to anticonvulsant drugs in utero. Nippon Sanka Fujinka Gakkai Zasshi 1991; 43(3): 347–50PubMedGoogle Scholar
  63. 63.
    Motohara K, Kuroki Y, Kan H, et al. Detection of vitamin K deficiency by use of an enzyme-linked immunosorbent assay for circulating abnormal prothrombin. Pediatr Res 1985; 19: 354–7PubMedCrossRefGoogle Scholar
  64. 64.
    Widdershove J, Lamver W. Motohara K, et al. Plasma concentrations of vitamin K and PIVKA-II in bottle-fed and breastfed infants with and without vitamin K prophylaxis at birth. Eur J Pediatr 1988; 148: 139–42Google Scholar
  65. 65.
    Cornelissen M, Steggers-Theunisse R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol 1993; 168: 923–7PubMedGoogle Scholar
  66. 66.
    Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation for vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol 1993; 168 (3 Pt 1): 884–8PubMedGoogle Scholar
  67. 67.
    Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21(6): 663–80PubMedCrossRefGoogle Scholar
  68. 68.
    Fujioka K, Kaneko S, Hirano T, et al. A study of the psychomotor development of the offspring of epileptic mothers. In: Sato T, Shinagawa S, editors. Antiepileptic drugs and pregnancy. Amsterdam: Excerpta Medica, 1984: 196–206Google Scholar
  69. 69.
    Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981–90PubMedCrossRefGoogle Scholar
  70. 70.
    Sophocles AM, Brozovich EM. Birth control failure among patients with unwanted pregnancies: 1982-1984. J Fam Pract 1986; 22(1): 45–8PubMedGoogle Scholar
  71. 71.
    American Collage of Obstetricians and Gynecologists: Seizure disorders in pregnancy. ACOG educational bulletin Number 231, December 1996. Committee on Educational Bulletins of the International Journal of Gynaecology and Obstetrics 1997; 56(3): 279–86Google Scholar
  72. 72.
    Mattson RH, Cramer JA, Darney PD, et al. Use of oral contraceptives by women with epilepsy. JAMA 1986; 256(2): 238–40PubMedCrossRefGoogle Scholar
  73. 73.
    Koren G, Nulman I. Fetal malformations associated with drugs and chemicals: visualization by sonography. In: Koren G, editor. Maternal-fetal toxicology: a clinician’s guide. 2nd. rev. ed. New York: Marcel Dekker, Inc., 1994: 627–39Google Scholar
  74. 74.
    Mazzotta P, Gupta A, Maltepe C, et al. Pharmacology treatment of nausea and vomiting during pregnancy. Can Family Phys 1998; 44: 1499–557Google Scholar
  75. 75.
    Erick M. Nausea and vomiting in pregnancy. ACOG Clin Rev 1997; 2: 1–2, 14-6CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.The Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Paediatrics, Hospital for Sick ChildrenUniversity of TorontoTorontoCanada

Personalised recommendations